Sanofi SA and GSK plc were beat to market during the first wave of COVID-19 by vaccines from upstarts such as Biontech SE and Moderna Inc. – but the French and U.K. vaccine specialists are gaining traction in the race to develop booster shots against newer variants.
The EMA has a list and it’ll be checking it frequently to avoid shortages with the help of COVID-19 marketing authorization holders and EU members states.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 4basebio, Anpac Bio-Medical Science, Bavarian Nordic, Chromadex, Critical Path Institute, Cyanvac, Eleusis, Frederick Gardner Cottrell Foundation, Genmab, Gritstone, Halozyme, Janssen, Kinarus, Perfect Holding, Silver Spike.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adverum, Alnylam, Aptevo, Brii, Cend, Fusion, Immunome, Lyndra, Olema, Takeda, Tryp, Verona, Zhittya.
More than two years into the COVID-19 pandemic and nearly 18 months since a vaccine was first available for adults, the U.S. is on the cusp of having vaccines available to the youngest Americans.
Based on a preliminary data analysis of its second and newest COVID-19 booster candidate, Moderna Inc. said it plans to ask the U.S. FDA to approve mRNA-1273.214 ahead of potential shipping in late summer 2022. The vaccine contains mRNA-1273 (Spikevax) and a vaccine candidate targeting omicron. New phase II/III results show the candidate hitting all the study’s primary endpoints when compared to Moderna’s original vaccine, mRNA-1273.
RSS
